We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

In Setback for Glaxo, U.K. Invalidates Paxil Patent

Law360 (October 31, 2005, 12:00 AM EST) -- The U.K. House of Lords has upheld a lower court’s decision to invalidate the patent for the key ingredient in GlaxoSmithKline’s Paxil, one of the world’s most widely prescribed antidepressants.

The Lords ruled in late October that Glaxo’s patent for the compound paroxetine mesylate was invalid and upheld an appeal brought by challenger Synthon against the decision of the Court of Appeal, which was made in June 2003. Paroxetine mesylate incorporates the main ingredient of Paxil, one of Glaxo’s best selling drugs.

Synthon challenged the validity...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.